Breaking News Instant updates and real-time market news.

MSGM

Motorsport Games

$23.57 /

-2.33 (-9.00%)

16:32
03/03/21
03/03
16:32
03/03/21
16:32

Motorsport Games to acquire Studio397 BV

Motorsport Games announced that it has entered a binding term sheet to acquire Studio397 BV, the company behind the industry leading rFactor 2 racing simulation platform, from Luminis International BV. The acquisition will see Studio397 continue its work on rFactor 2 while also developing the physics and handling models for Motorsport Games' forthcoming projects. Motorsport Games expects to utilize its resources and expertise to enhance the rFactor 2 offering, especially in areas highlighted by the racing community. Studio397 and Motorsport Games have long worked in tandem, with rFactor 2 providing the simulation platform for the highly successful 24 Hours of Le Mans Virtual race, as well as the Formula E Race at Home Challenge, both of which were operated by Motorsport Games. It is expected that Studio397 will retain its name and branding with the existing development team and management will remain with the studio.

  • 24

    Mar

  • 13

    Jan

MSGM Motorsport Games
$23.57 /

-2.33 (-9.00%)

02/22/21 Canaccord
Motorsport Games portfolio strengthened with KartKraft buy, says Canaccord
02/08/21 Benchmark
Motorsport Games initiated with a Buy at Benchmark
02/08/21 Canaccord
Motorsport Games initiated with a Buy at Canaccord

TODAY'S FREE FLY STORIES

Conference/Events
American Association for Cancer Research to hold a virtual meeting » 04:55
04/11/21
04/11
04:55
04/11/21
04:55
MDGEF

MediGene

$4.80 /

+ (+0.00%)

, GLSI

Greenwich LifeSciences

$53.50 /

+4.21 (+8.54%)

, JNCE

Jounce Therapeutics

$9.76 /

-0.65 (-6.24%)

, ATNM

Actinium Pharmaceuticals

$8.10 /

-0.085 (-1.04%)

, BDTX

Black Diamond Therapeutics

$24.61 /

-0.31 (-1.24%)

, CRSP

Crispr Therapeutics

$115.49 /

-4.67 (-3.89%)

, HARP

Harpoon Therapeutics

$22.70 /

-0.03 (-0.13%)

, ITOS

iTeos Therapeutics

$26.99 /

-3.12 (-10.36%)

, REPL

Replimune Group

$30.04 /

-0.52 (-1.70%)

, RVMD

Revolution Medicines

$42.65 /

-2.46 (-5.45%)

, ZNTL

Zentalis

$37.35 /

-5.19 (-12.20%)

, IMCR

Immunocore

$35.01 /

-0.99 (-2.75%)

, PMVP

PMV Pharmaceuticals

$33.30 /

-0.605 (-1.78%)

, ARVN

Arvinas

$63.55 /

-0.83 (-1.29%)

, IOVA

Iovance Biotherapeutics

$30.17 /

-1.12 (-3.58%)

, ADXS

Advaxis

/

+

, AGEN

Agenus

$2.78 /

-0.01 (-0.36%)

, BPTH

Bio-Path

$6.79 /

-0.13 (-1.88%)

, INCY

Incyte

$79.97 /

-0.91 (-1.13%)

, IMAB

I-MAB

$51.50 /

-1.34 (-2.54%)

, MRSN

Mersana Therapeutics

$15.79 /

-0.27 (-1.68%)

, RUBY

Rubius Therapeutics

$23.92 /

-0.14 (-0.58%)

, PPBT

Purple Biotech

$4.31 /

+0.035 (+0.82%)

, SONN

Sonnet BioTherapeutics

$2.24 /

-0.05 (-2.18%)

, STTK

Shattuck Labs

$28.31 /

+1.365 (+5.07%)

, SURF

Surface Oncology

$7.93 /

-0.22 (-2.70%)

, BGNE

BeiGene

$308.27 /

-5.8 (-1.85%)

, CMPI

Checkmate Pharmaceuticals

$10.52 /

+0.14 (+1.35%)

, BNGO

Bionano Genomics

$7.29 /

-0.215 (-2.87%)

AACR Virtual Annual…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GLSI Greenwich LifeSciences
$53.50 /

+4.21 (+8.54%)

JNCE Jounce Therapeutics
$9.76 /

-0.65 (-6.24%)

ATNM Actinium Pharmaceuticals
$8.10 /

-0.085 (-1.04%)

BDTX Black Diamond Therapeutics
$24.61 /

-0.31 (-1.24%)

CRSP Crispr Therapeutics
$115.49 /

-4.67 (-3.89%)

HARP Harpoon Therapeutics
$22.70 /

-0.03 (-0.13%)

ITOS iTeos Therapeutics
$26.99 /

-3.12 (-10.36%)

REPL Replimune Group
$30.04 /

-0.52 (-1.70%)

RVMD Revolution Medicines
$42.65 /

-2.46 (-5.45%)

ZNTL Zentalis
$37.35 /

-5.19 (-12.20%)

IMCR Immunocore
$35.01 /

-0.99 (-2.75%)

PMVP PMV Pharmaceuticals
$33.30 /

-0.605 (-1.78%)

ARVN Arvinas
$63.55 /

-0.83 (-1.29%)

IOVA Iovance Biotherapeutics
$30.17 /

-1.12 (-3.58%)

ADXS Advaxis
/

+

AGEN Agenus
$2.78 /

-0.01 (-0.36%)

BPTH Bio-Path
$6.79 /

-0.13 (-1.88%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

IMAB I-MAB
$51.50 /

-1.34 (-2.54%)

MRSN Mersana Therapeutics
$15.79 /

-0.27 (-1.68%)

RUBY Rubius Therapeutics
$23.92 /

-0.14 (-0.58%)

PPBT Purple Biotech
$4.31 /

+0.035 (+0.82%)

SONN Sonnet BioTherapeutics
$2.24 /

-0.05 (-2.18%)

STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

SURF Surface Oncology
$7.93 /

-0.22 (-2.70%)

BGNE BeiGene
$308.27 /

-5.8 (-1.85%)

CMPI Checkmate Pharmaceuticals
$10.52 /

+0.14 (+1.35%)

BNGO Bionano Genomics
$7.29 /

-0.215 (-2.87%)

MDGEF MediGene
$4.80 /

+ (+0.00%)

GLSI Greenwich LifeSciences
$53.50 /

+4.21 (+8.54%)

JNCE Jounce Therapeutics
$9.76 /

-0.65 (-6.24%)

03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
12/04/20 H.C. Wainwright
Jounce Therapeutics assumed with a Buy at H.C. Wainwright
11/10/20 Roth Capital
Jounce Therapeutics price target lowered to $15 from $28 at Roth Capital
ATNM Actinium Pharmaceuticals
$8.10 /

-0.085 (-1.04%)

04/06/21 William Blair
Actinium's Q4 net loss roughly in line with projected loss, says William Blair
12/29/20 H.C. Wainwright
H.C. Wainwright keeps Buy on Actinium amid 'headline disappointment'
12/29/20 JonesTrading
Actinium selloff today 'clear buying opportunity,' says JonesTrading
11/05/20
Fly Intel: Top five analyst initiations
BDTX Black Diamond Therapeutics
$24.61 /

-0.31 (-1.24%)

03/29/21 Wedbush
Black Diamond Therapeutics added to Best Ideas List at Wedbush
01/07/21 Wedbush
Wedbush bullish on Black Diamond Therapeutics, initiates with an Outperform
01/06/21 Wedbush
Black Diamond Therapeutics initiated with an Outperform at Wedbush
11/24/20 Berenberg
Black Diamond Therapeutics initiated with a Buy at Berenberg
CRSP Crispr Therapeutics
$115.49 /

-4.67 (-3.89%)

03/17/21 Guggenheim
Editas Medicine assumed with a Neutral at Guggenheim
03/04/21 JMP Securities
Crispr Therapeutics initiated with an Outperform at JMP Securities
03/01/21 Barclays
Crispr Therapeutics price target raised to $140 from $113 at Barclays
02/17/21 Goldman Sachs
Crispr Therapeutics price target lowered to $189 from $193 at Goldman Sachs
HARP Harpoon Therapeutics
$22.70 /

-0.03 (-0.13%)

03/11/21 Roth Capital
Harpoon's 2020/2021 should be 'festival of data,' says Roth Capital
01/04/21 Roth Capital
Harpoon having fourth candidate in clinic 'impressive,' says Roth Capital
12/23/20 H.C. Wainwright
Harpoon Therapeutics assumed with a Buy at H.C. Wainwright
12/16/20 Wedbush
Replimune Group, Harpoon Therapeutics removed from Best Ideas List at Wedbush
ITOS iTeos Therapeutics
$26.99 /

-3.12 (-10.36%)

04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
04/05/21 Piper Sandler
Piper Sandler continues to recommend iTeos Therapeutics into data
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
REPL Replimune Group
$30.04 /

-0.52 (-1.70%)

02/05/21 H.C. Wainwright
Replimune Group price target raised to $60 from $58 at H.C. Wainwright
12/16/20 Wedbush
Replimune Group, Harpoon Therapeutics removed from Best Ideas List at Wedbush
11/17/20 BTIG
Replimune Group initiated with a Buy at BTIG
11/10/20 H.C. Wainwright
Replimune Group price target raised to $58 from $54 at H.C. Wainwright
RVMD Revolution Medicines
$42.65 /

-2.46 (-5.45%)

03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
ZNTL Zentalis
$37.35 /

-5.19 (-12.20%)

03/26/21 H.C. Wainwright
Zentalis price target raised to $65 from $43 at H.C. Wainwright
01/19/21 Wedbush
Zentalis initiated with an Outperform at Wedbush
09/28/20 Cantor Fitzgerald
Cantor starts 'underappreciated' Zentalis with Overweight, $44 target
09/28/20 Cantor Fitzgerald
Zentalis initiated with an Overweight at Cantor Fitzgerald
IMCR Immunocore
$35.01 /

-0.99 (-2.75%)

03/02/21 Jefferies
Immunocore initiated with a Buy at Jefferies
03/02/21 JPMorgan
Immunocore initiated with an Overweight at JPMorgan
03/02/21 Goldman Sachs
Immunocore initiated with a Neutral at Goldman Sachs
PMVP PMV Pharmaceuticals
$33.30 /

-0.605 (-1.78%)

10/20/20 Evercore ISI
PMV Pharmaceuticals initiated with an Outperform at Evercore ISI
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 Cowen
PMV Pharmaceuticals initiated with an Outperform at Cowen
ARVN Arvinas
$63.55 /

-0.83 (-1.29%)

03/31/21 BMO Capital
Arvinas initiated with an Outperform at BMO Capital
03/30/21 Cantor Fitzgerald
Arvinas price target raised to $140 from $121 at Cantor Fitzgerald
03/01/21 Roth Capital
Arvinas reaffirmed 'major catalysts' for 2021, says Roth Capital
01/19/21 Oppenheimer
Arvinas price target raised to $100 from $80 at Oppenheimer
IOVA Iovance Biotherapeutics
$30.17 /

-1.12 (-3.58%)

03/08/21 H.C. Wainwright
Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright
01/29/21 Baird
Iovance Biotherapeutics assumed at Outperform at Baird
01/14/21 Oppenheimer
Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer
12/17/20 Barclays
Iovance Biotherapeutics price target raised to $55 from $43 at Barclays
ADXS Advaxis
/

+

AGEN Agenus
$2.78 /

-0.01 (-0.36%)

09/22/20 B. Riley FBR
B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases
09/18/20 Jefferies
Agenus price target raised to $8 from $5 at Jefferies
BPTH Bio-Path
$6.79 /

-0.13 (-1.88%)

04/06/21 H.C. Wainwright
Bio-Path price target raised to $12 from $10 at H.C. Wainwright
04/05/21 Roth Capital
Bio-Path triple regimen data 'highly favorable,' says Roth Capital
03/11/21 Roth Capital
Bio-Path Holdings initiated with a Buy at Roth Capital
11/16/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $10 from $12 at H.C. Wainwright
INCY Incyte
$79.97 /

-0.91 (-1.13%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
IMAB I-MAB
$51.50 /

-1.34 (-2.54%)

03/15/21 Needham
I-MAB initiated with a Buy at Needham
03/03/21 H.C. Wainwright
I-MAB price target raised to $75 from $55 at H.C. Wainwright
02/25/21
Fly Intel: Top five analyst initiations
02/25/21 Piper Sandler
I-MAB initiated with an Overweight at Piper Sandler
MRSN Mersana Therapeutics
$15.79 /

-0.27 (-1.68%)

03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
12/02/20 Stifel
Mersana Therapeutics initiated with a Buy at Stifel
09/29/20 JPMorgan
Mersana Therapeutics resumed with a Neutral at JPMorgan
RUBY Rubius Therapeutics
$23.92 /

-0.14 (-0.58%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
PPBT Purple Biotech
$4.31 /

+0.035 (+0.82%)

12/31/20 H.C. Wainwright
H.C. Wainwright reiterates Buy, $25 price target on Purple Biotech
SONN Sonnet BioTherapeutics
$2.24 /

-0.05 (-2.18%)

09/04/20 Chardan
Sonnet BioTherapeutics price target raised to $8 from $7 at Chardan
06/05/20 Chardan
Sonnet BioTherapeutics initiated with a Buy at Chardan
STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
01/11/21 Evercore ISI
Shattuck Labs initiated with an Outperform at Evercore ISI
11/03/20 Needham
Shattuck Labs initiated with a Buy at Needham
11/03/20 Citi
Shattuck Labs initiated with a Buy at Citi
SURF Surface Oncology
$7.93 /

-0.22 (-2.70%)

03/10/21 Wedbush
Surface Oncology risk/reward 'highly favorable' into data, says Wedbush
12/18/20 H.C. Wainwright
Surface Oncology price target raised to $15 from $11 at H.C. Wainwright
09/04/20
Fly Intel: Top five analyst initiations
09/04/20 H.C. Wainwright
Surface Oncology initiated with a Buy at H.C. Wainwright
BGNE BeiGene
$308.27 /

-5.8 (-1.85%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
CMPI Checkmate Pharmaceuticals
$10.52 /

+0.14 (+1.35%)

03/19/21 Jefferies
Checkmate Pharmaceuticals price target lowered to $19 from $23 at Jefferies
09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
09/01/20 BofA
BofA starts Checkmate Pharmaceuticals at Neutral ahead of more 'de-risking'
09/01/20 BofA
Checkmate Pharmaceuticals initiated with a Neutral at BofA
BNGO Bionano Genomics
$7.29 /

-0.215 (-2.87%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
JNCE Jounce Therapeutics
$9.76 /

-0.65 (-6.24%)

BDTX Black Diamond Therapeutics
$24.61 /

-0.31 (-1.24%)

CRSP Crispr Therapeutics
$115.49 /

-4.67 (-3.89%)

HARP Harpoon Therapeutics
$22.70 /

-0.03 (-0.13%)

ITOS iTeos Therapeutics
$26.99 /

-3.12 (-10.36%)

REPL Replimune Group
$30.04 /

-0.52 (-1.70%)

RVMD Revolution Medicines
$42.65 /

-2.46 (-5.45%)

ZNTL Zentalis
$37.35 /

-5.19 (-12.20%)

IMCR Immunocore
$35.01 /

-0.99 (-2.75%)

PMVP PMV Pharmaceuticals
$33.30 /

-0.605 (-1.78%)

ARVN Arvinas
$63.55 /

-0.83 (-1.29%)

IOVA Iovance Biotherapeutics
$30.17 /

-1.12 (-3.58%)

ADXS Advaxis
/

+

AGEN Agenus
$2.78 /

-0.01 (-0.36%)

BPTH Bio-Path
$6.79 /

-0.13 (-1.88%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

MRSN Mersana Therapeutics
$15.79 /

-0.27 (-1.68%)

RUBY Rubius Therapeutics
$23.92 /

-0.14 (-0.58%)

STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

SURF Surface Oncology
$7.93 /

-0.22 (-2.70%)

BGNE BeiGene
$308.27 /

-5.8 (-1.85%)

CMPI Checkmate Pharmaceuticals
$10.52 /

+0.14 (+1.35%)

BNGO Bionano Genomics
$7.29 /

-0.215 (-2.87%)

  • 17
    Mar
  • 10
    Mar
  • 16
    Feb
  • 09
    Feb
  • 05
    Feb
  • 04
    Feb
  • 20
    Jan
  • 13
    Jan
  • 08
    Jan
  • 07
    Jan
  • 18
    Dec
  • 16
    Dec
  • 02
    Dec
  • 24
    Nov
  • 22
    Oct
  • 09
    Oct
  • 25
    Sep
  • 25
    Sep
  • 07
    Aug
  • 30
    Jul
  • 24
    Jul
  • 09
    Jul
  • 01
    Jul
  • 17
    Jun
  • 09
    Jun
  • 29
    May
  • 29
    May
  • 22
    Apr
GLSI Greenwich LifeSciences
$53.50 /

+4.21 (+8.54%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

GLSI Greenwich LifeSciences
$53.50 /

+4.21 (+8.54%)

JNCE Jounce Therapeutics
$9.76 /

-0.65 (-6.24%)

ATNM Actinium Pharmaceuticals
$8.10 /

-0.085 (-1.04%)

CRSP Crispr Therapeutics
$115.49 /

-4.67 (-3.89%)

HARP Harpoon Therapeutics
$22.70 /

-0.03 (-0.13%)

REPL Replimune Group
$30.04 /

-0.52 (-1.70%)

RVMD Revolution Medicines
$42.65 /

-2.46 (-5.45%)

IMCR Immunocore
$35.01 /

-0.99 (-2.75%)

ARVN Arvinas
$63.55 /

-0.83 (-1.29%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

MRSN Mersana Therapeutics
$15.79 /

-0.27 (-1.68%)

RUBY Rubius Therapeutics
$23.92 /

-0.14 (-0.58%)

STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

SURF Surface Oncology
$7.93 /

-0.22 (-2.70%)

BNGO Bionano Genomics
$7.29 /

-0.215 (-2.87%)

BDTX Black Diamond Therapeutics
$24.61 /

-0.31 (-1.24%)

CRSP Crispr Therapeutics
$115.49 /

-4.67 (-3.89%)

REPL Replimune Group
$30.04 /

-0.52 (-1.70%)

RVMD Revolution Medicines
$42.65 /

-2.46 (-5.45%)

ZNTL Zentalis
$37.35 /

-5.19 (-12.20%)

PMVP PMV Pharmaceuticals
$33.30 /

-0.605 (-1.78%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

IMAB I-MAB
$51.50 /

-1.34 (-2.54%)

PPBT Purple Biotech
$4.31 /

+0.035 (+0.82%)

BNGO Bionano Genomics
$7.29 /

-0.215 (-2.87%)

Conference/Events
Barfresh Food Group to host business news update conference call » 16:52
04/10/21
04/10
16:52
04/10/21
16:52
BRFH

Barfresh Food Group

/

+

Management holds a…

Management holds a business news update conference call on April 14 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
BRFH Barfresh Food Group
/

+

BRFH Barfresh Food Group
/

+

04/13/20
Barfresh Food Group to host business news update conference call
Conference/Events
Rackspace Technology to hold a virtual roundtable » 16:37
04/10/21
04/10
16:37
04/10/21
16:37
FORR

Forrester

$41.61 /

-0.315 (-0.75%)

, DELL

Dell Technologies

$93.88 /

+1.18 (+1.27%)

, RXT

Rackspace Technology

$26.07 /

+0.46 (+1.80%)

Virtual Roundtable…

Virtual Roundtable entitled, "What Your Cloud Strategy May Be Overlooking" will be held on April 12 at 11 am. Webcast Link

ShowHide Related Items >><<
RXT Rackspace Technology
$26.07 /

+0.46 (+1.80%)

DELL Dell Technologies
$93.88 /

+1.18 (+1.27%)

FORR Forrester
$41.61 /

-0.315 (-0.75%)

02/16/21 Barrington
Forrester price target raised to $50 from $44 at Barrington
08/03/20 Barrington
Forrester price target raised to $44 from $40 at Barrington
DELL Dell Technologies
$93.88 /

+1.18 (+1.27%)

04/08/21 Morgan Stanley
Dell Technologies price target raised to $107 from $98 at Morgan Stanley
04/07/21 Deutsche Bank
Dell Technologies price target raised to $100 from $94 at Deutsche Bank
02/26/21 JPMorgan
Dell Technologies price target raised to $98 from $90 at JPMorgan
02/26/21 Credit Suisse
Dell Technologies price target raised to $80 from $70 at Credit Suisse
RXT Rackspace Technology
$26.07 /

+0.46 (+1.80%)

04/01/21 William Blair
William Blair starts Rackspace with Outperform, sees 30% upside
03/31/21 William Blair
Rackspace Technology initiated with an Outperform at William Blair
01/25/21 Oppenheimer
Rackspace Technology initiated with an Outperform at Oppenheimer
09/01/20 BMO Capital
Rackspace Technology price target raised to $25 from $23 at BMO Capital
RXT Rackspace Technology
$26.07 /

+0.46 (+1.80%)

FORR Forrester
$41.61 /

-0.315 (-0.75%)

DELL Dell Technologies
$93.88 /

+1.18 (+1.27%)

  • 05
    Aug
RXT Rackspace Technology
$26.07 /

+0.46 (+1.80%)

DELL Dell Technologies
$93.88 /

+1.18 (+1.27%)

RXT Rackspace Technology
$26.07 /

+0.46 (+1.80%)

DELL Dell Technologies
$93.88 /

+1.18 (+1.27%)

RXT Rackspace Technology
$26.07 /

+0.46 (+1.80%)

DELL Dell Technologies
$93.88 /

+1.18 (+1.27%)

Conference/Events
REV Group to host virtual investor meeting » 16:32
04/10/21
04/10
16:32
04/10/21
16:32
REVG

REV Group

$18.75 /

+0.11 (+0.59%)

Virtual Investor Meeting…

Virtual Investor Meeting to be held on April 15 at 10 am. Webcast Link

ShowHide Related Items >><<
REVG REV Group
$18.75 /

+0.11 (+0.59%)

REVG REV Group
$18.75 /

+0.11 (+0.59%)

03/12/21 BMO Capital
REV Group price target raised to $19 from $10 at BMO Capital
03/11/21 Morgan Stanley
REV Group price target raised to $18 from $10 at Morgan Stanley
03/10/21 Baird
REV Group price target raised to $22 from $20 at Baird
03/10/21 Baird
REV Group continues to benefit from stimulus funding, says Baird
REVG REV Group
$18.75 /

+0.11 (+0.59%)

REVG REV Group
$18.75 /

+0.11 (+0.59%)

Conference/Events
Palantir hosts a Double Click virtual demo event » 16:29
04/10/21
04/10
16:29
04/10/21
16:29
PLTR

Palantir

$24.03 /

+0.64 (+2.74%)

Management holds a Double…

Management holds a Double Click demo virtual event to showcase how the platforms are used across industries and customers. Please note that capacity is limited and registration will close 24 hours prior to the event being held on April 14 at 11 am. Webcast Link

ShowHide Related Items >><<
PLTR Palantir
$24.03 /

+0.64 (+2.74%)

PLTR Palantir
$24.03 /

+0.64 (+2.74%)

03/15/21 Credit Suisse
Palantir assumed with an Underperform at Credit Suisse
02/17/21
Fly Intel: Top five analyst upgrades
02/17/21 RBC Capital
Palantir price target raised to $27 from $15 at RBC Capital
02/17/21 Jefferies
Palantir 'a highly unique story for long-term investors,' says Jefferies
PLTR Palantir
$24.03 /

+0.64 (+2.74%)

PLTR Palantir
$24.03 /

+0.64 (+2.74%)

PLTR Palantir
$24.03 /

+0.64 (+2.74%)

PLTR Palantir
$24.03 /

+0.64 (+2.74%)

Conference/Events
Moderna to hold a virtual meeting » 16:18
04/10/21
04/10
16:18
04/10/21
16:18
MRNA

Moderna

$140.82 /

+7.05 (+5.27%)

Moderna Virtual Vaccines…

Moderna Virtual Vaccines Day to be held on April 14 at 8 am. Webcast Link

ShowHide Related Items >><<
MRNA Moderna
$140.82 /

+7.05 (+5.27%)

MRNA Moderna
$140.82 /

+7.05 (+5.27%)

04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
03/01/21 Chardan
Moderna price target raised to $182 from $107 at Chardan
02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
MRNA Moderna
$140.82 /

+7.05 (+5.27%)

  • 19
    May
MRNA Moderna
$140.82 /

+7.05 (+5.27%)

MRNA Moderna
$140.82 /

+7.05 (+5.27%)

MRNA Moderna
$140.82 /

+7.05 (+5.27%)

Conference/Events
Howard Hughes to hold virtual investor day » 16:16
04/10/21
04/10
16:16
04/10/21
16:16
HHC

Howard Hughes

$99.77 /

-0.01 (-0.01%)

Virtual Investor Day to…

Virtual Investor Day to be held on April 14 at 10:30 am. Webcast Link

ShowHide Related Items >><<
HHC Howard Hughes
$99.77 /

-0.01 (-0.01%)

HHC Howard Hughes
$99.77 /

-0.01 (-0.01%)

03/01/21 Piper Sandler
Howard Hughes price target raised to $115 from $100 at Piper Sandler
02/16/21 BWS Financial
Howard Hughes price target raised to $150 from $80 at BWS Financial
01/11/21 Piper Sandler
Howard Hughes price target raised to $100 from $90 at Piper Sandler
09/22/20 BWS Financial
Howard Hughes could evaluate options again after CEO exit, says BWS Financial
HHC Howard Hughes
$99.77 /

-0.01 (-0.01%)

Conference/Events
KKR to host virtual investor day » 16:14
04/10/21
04/10
16:14
04/10/21
16:14
KKR

KKR

$51.36 /

-0.27 (-0.52%)

Virtual Investor Day to…

Virtual Investor Day to be held on April 13 at 8:30 am. Webcast Link

ShowHide Related Items >><<
KKR KKR
$51.36 /

-0.27 (-0.52%)

KKR KKR
$51.36 /

-0.27 (-0.52%)

04/09/21 DA Davidson
Box price target lowered to $22 from $25 at DA Davidson
04/09/21 William Blair
KKR investment 'strong vote of confidence' in Box, says William Blair
04/09/21 William Blair
KKR investment 'strong vote of confidence' in Box, says William Blair
04/07/21 Seaport Global
Seaport downgrades Sempra Energy to Neutral after 'good, not great' SIP deal
KKR KKR
$51.36 /

-0.27 (-0.52%)

  • 11
    Nov
KKR KKR
$51.36 /

-0.27 (-0.52%)

KKR KKR
$51.36 /

-0.27 (-0.52%)

Conference/Events
Blueprint Medicines to host conference call » 16:10
04/10/21
04/10
16:10
04/10/21
16:10
BPMC

Blueprint Medicines

$94.14 /

+0.25 (+0.27%)

Management reviews new…

Management reviews new data for multiple research and clinical-stage programs across the Company's precision oncology and hematology portfolio on a conference call to be held on April 12 at 8 am. Webcast Link

ShowHide Related Items >><<
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
02/18/21 Barclays
Blueprint Medicines price target raised to $95 from $90 at Barclays
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

Periodicals
Goldman Sachs had strong pandemic, still room to run, Barron's says » 10:06
04/10/21
04/10
10:06
04/10/21
10:06
GS

Goldman Sachs

$330.85 /

-0.13 (-0.04%)

Goldman Sachs Group stock…

Goldman Sachs Group stock has gained 67% since last June-and there's no reason it can't keep rising, Carleton English writes in this week's edition of Barron's. Reference Link

ShowHide Related Items >><<
GS Goldman Sachs
$330.85 /

-0.13 (-0.04%)

GS Goldman Sachs
$330.85 /

-0.13 (-0.04%)

04/09/21 JMP Securities
Goldman Sachs price target raised to $400 from $338 at JMP Securities
04/08/21 Citi
Goldman Sachs price target raised to $390 from $370 at Citi
04/07/21 Barclays
Goldman Sachs price target raised to $420 from $392 at Barclays
04/01/21
Fly Intel: Top five analyst downgrades
GS Goldman Sachs
$330.85 /

-0.13 (-0.04%)

GS Goldman Sachs
$330.85 /

-0.13 (-0.04%)

GS Goldman Sachs
$330.85 /

-0.13 (-0.04%)

GS Goldman Sachs
$330.85 /

-0.13 (-0.04%)

Periodicals
Credit Suisse crises slamming stock, investors should stay away, Barron's says » 10:04
04/10/21
04/10
10:04
04/10/21
10:04
CS

Credit Suisse

$10.64 /

-0.305 (-2.79%)

It's too soon to…

It's too soon to wade into the shares of Credit Suisse, with the stock plunging as the bank struggles with the latest in a series of crises that began a year ago, Paul Clarke writes in this week's edition of Barron's. But tempting as the stock price may now be, more challenges could well lie ahead, adds the author. Reference Link

ShowHide Related Items >><<
CS Credit Suisse
$10.64 /

-0.305 (-2.79%)

CS Credit Suisse
$10.64 /

-0.305 (-2.79%)

04/09/21
Fly Intel: Top five analyst downgrades
04/09/21 Morgan Stanley
Credit Suisse downgraded to Equal Weight from Overweight at Morgan Stanley
04/07/21 RBC Capital
Credit Suisse price target lowered to CHF 11 from CHF 14.50 at RBC Capital
04/07/21 Exane BNP Paribas
Credit Suisse downgraded to Neutral from Outperform at Exane BNP Paribas
CS Credit Suisse
$10.64 /

-0.305 (-2.79%)

CS Credit Suisse
$10.64 /

-0.305 (-2.79%)

CS Credit Suisse
$10.64 /

-0.305 (-2.79%)

CS Credit Suisse
$10.64 /

-0.305 (-2.79%)

Periodicals
Affirm stock still 'a good play' on future of shopping, Barron's says » 10:02
04/10/21
04/10
10:02
04/10/21
10:02
AFRM

Affirm

$70.60 /

+0.81 (+1.16%)

The next few months…

The next few months should be boom times for retailers as stimulus checks pump up the economy, but consumers aren't shopping the way they used to as they are souring on credit, and they are increasingly likely to shop online with a digital wallet rather than pull out cash in a store, Daren Fonda writes in this week's edition of Barron's. The trends are fueling the "buy now, pay later," and they could lift the shares of Affirm Holdings, adds the author. Reference Link

ShowHide Related Items >><<
AFRM Affirm
$70.60 /

+0.81 (+1.16%)

AFRM Affirm
$70.60 /

+0.81 (+1.16%)

03/25/21 BofA
Affirm initiated with a Neutral at BofA
03/17/21 Wedbush
LendingClub price target raised to $20.50 from $14 at Wedbush
03/17/21 Deutsche Bank
Affirm price target lowered to $92 from $120 at Deutsche Bank
02/16/21 Barclays
Affirm price target raised to $148 from $132 at Barclays
AFRM Affirm
$70.60 /

+0.81 (+1.16%)

  • 13
    Jan
AFRM Affirm
$70.60 /

+0.81 (+1.16%)

AFRM Affirm
$70.60 /

+0.81 (+1.16%)

AFRM Affirm
$70.60 /

+0.81 (+1.16%)

Periodicals
BorgWarner ready as EV future nearly here, Barron's says » 09:58
04/10/21
04/10
09:58
04/10/21
09:58
BWA

BorgWarner

$46.46 /

+0.43 (+0.93%)

U.S. has been slow to go…

U.S. has been slow to go electric, but could catch up soon and BorgWarner has prepared for this moment gradually over the past eight or so years by designing components like electric drive modules, Jack Hough writes in this week's edition of Barron's. Last year, it bought Delphi Technologies, which adds power electronics to make plug-in cars more efficient, adds the author. Yet while BorgWarner shares have bounced back from last year's market collapse, they're still below where they were three years ago, notes the publication. Reference Link

ShowHide Related Items >><<
BWA BorgWarner
$46.46 /

+0.43 (+0.93%)

BWA BorgWarner
$46.46 /

+0.43 (+0.93%)

04/06/21 Jefferies
BorgWarner price target raised to $54 from $50 at Jefferies
03/25/21 Wells Fargo
BorgWarner initiated with an Overweight at Wells Fargo
03/25/21 Deutsche Bank
BorgWarner price target lowered to $40 from $45 at Deutsche Bank
03/24/21 RBC Capital
BorgWarner price target raised to $43 from $41 at RBC Capital
BWA BorgWarner
$46.46 /

+0.43 (+0.93%)

BWA BorgWarner
$46.46 /

+0.43 (+0.93%)

BWA BorgWarner
$46.46 /

+0.43 (+0.93%)

Periodicals
II-VI on the cutting edge, stock looks cheap, Barron's says » 09:58
04/10/21
04/10
09:58
04/10/21
09:58
IIVI

II-VI

$76.26 /

+0.04 (+0.05%)

, COHR

Coherent

$265.71 /

+1.86 (+0.70%)

, LITE

Lumentum

$91.17 /

-0.08 (-0.09%)

, MKSI

MKS Instruments

$191.42 /

-2.77 (-1.43%)

For decades, the laser…

For decades, the laser industry has been a fragmented collection of small players, but a wave of mergers is changing the dynamic, creating long-term opportunities for investors, Nicholas Jasinski writes in this week's edition of Barron's. Industry leader II-VI (IIVI) recently earned the winning bid for optical component maker Coherent (COHR) as rival offers from competitors Lumentum (LITE) and MKS Instruments (MKSI) forced II-VI to raise its offer several times and ultimately pay about $7B in cash and stock. II-VI's stock dropped from a high of nearly $100 to the mid-$60s when the bidding war came to a close, which was an overreaction, with the stock rebounding to about $76 in recent days, notes the author. But there's even more compelling value in the combination of II-VI and Coherent than the market is crediting, and the stock should regain the $100 level and continue moving higher from there, adds Jasinski. Reference Link

ShowHide Related Items >><<
MKSI MKS Instruments
$191.42 /

-2.77 (-1.43%)

LITE Lumentum
$91.17 /

-0.08 (-0.09%)

IIVI II-VI
$76.26 /

+0.04 (+0.05%)

IIVI II-VI
$76.26 /

+0.04 (+0.05%)

03/30/21 Canaccord
II-VI price target lowered to $125 from $152 at Canaccord
03/26/21 Northland
NeoPhotonics deal 'makes more sense than ever' for Lumentum, says Northland
03/26/21 Cowen
II-VI weakness on deal announcement a buying opportunity, says Cowen
03/26/21 B. Riley
II-VI upgraded to Buy from Neutral at B. Riley Securities
COHR Coherent
$265.71 /

+1.86 (+0.70%)

03/26/21 Raymond James
Lumentum upgraded to Strong Buy from Outperform at Raymond James
LITE Lumentum
$91.17 /

-0.08 (-0.09%)

03/18/21
Fly Intel: Top five analyst downgrades
MKSI MKS Instruments
$191.42 /

-2.77 (-1.43%)

02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
MKSI MKS Instruments
$191.42 /

-2.77 (-1.43%)

LITE Lumentum
$91.17 /

-0.08 (-0.09%)

IIVI II-VI
$76.26 /

+0.04 (+0.05%)

COHR Coherent
$265.71 /

+1.86 (+0.70%)

  • 02
    Jul
IIVI II-VI
$76.26 /

+0.04 (+0.05%)

COHR Coherent
$265.71 /

+1.86 (+0.70%)

MKSI MKS Instruments
$191.42 /

-2.77 (-1.43%)

IIVI II-VI
$76.26 /

+0.04 (+0.05%)

LITE Lumentum
$91.17 /

-0.08 (-0.09%)

Periodicals
Cruise Line stocks could sink, Barron's says » 09:43
04/10/21
04/10
09:43
04/10/21
09:43
CCL

Carnival

$29.30 /

+0.73 (+2.56%)

, NCLH

Norwegian Cruise Line

$30.53 /

-0.08 (-0.26%)

, RCL

Royal Caribbean

$89.86 /

+0.08 (+0.09%)

Facing a virtual shutdown…

Facing a virtual shutdown and suffering heavy losses, the three dominant cruise-line operators- Carnival (CCL), Norwegian Cruise Line Holdings (NCLH), and Royal Caribbean Group (RCL)-have raised a total of about $40B through debt and equity sales, Andrew Bary writes in this week's edition of Barron's. The debt and equity sales have left the three companies with ample cash to ride out the downturn, but they have come at a price, notes the author, adding that they will cut into investor returns because of higher interest expenses and a sharp increase in shares outstanding. But while bookings are strong, it is unclear whether travelers-and particularly older ones, an important demographic-will be as eager to go on cruises as they were before the pandemic, says Bary. Reference Link

ShowHide Related Items >><<
RCL Royal Caribbean
$89.86 /

+0.08 (+0.09%)

NCLH Norwegian Cruise Line
$30.53 /

-0.08 (-0.26%)

CCL Carnival
$29.30 /

+0.73 (+2.56%)

CCL Carnival
$29.30 /

+0.73 (+2.56%)

04/09/21
Fly Intel: Top five analyst upgrades
04/09/21 Argus
Carnival upgraded to Buy from Hold at Argus sees 'strong' pent-up cruise demand
04/09/21 Argus
Carnival upgraded to Buy from Hold at Argus
04/09/21 Credit Suisse
Carnival upgraded to Outperform from Neutral at Credit Suisse
NCLH Norwegian Cruise Line
$30.53 /

-0.08 (-0.26%)

03/24/21 Stifel
Cruiseline stock selloff 'unwarranted,' says Stifel
03/18/21 UBS
Norwegian Cruise Line price target raised to $32 from $21 at UBS
03/16/21 JPMorgan
Norwegian Cruise Line price target raised to $36 from $33 at JPMorgan
03/12/21 Truist
Norwegian Cruise Line price target raised to $25 from $20 at Truist
RCL Royal Caribbean
$89.86 /

+0.08 (+0.09%)

03/18/21 UBS
Royal Caribbean price target raised to $116 from $79 at UBS
03/16/21 JPMorgan
Royal Caribbean price target raised to $110 from $100 at JPMorgan
03/12/21 Truist
Royal Caribbean price target raised to $68 from $48 at Truist
RCL Royal Caribbean
$89.86 /

+0.08 (+0.09%)

NCLH Norwegian Cruise Line
$30.53 /

-0.08 (-0.26%)

CCL Carnival
$29.30 /

+0.73 (+2.56%)

  • 05
    Mar
  • 01
    Mar
  • 23
    Feb
  • 18
    Nov
  • 14
    Oct
  • 17
    Jul
  • 06
    May
NCLH Norwegian Cruise Line
$30.53 /

-0.08 (-0.26%)

CCL Carnival
$29.30 /

+0.73 (+2.56%)

NCLH Norwegian Cruise Line
$30.53 /

-0.08 (-0.26%)

CCL Carnival
$29.30 /

+0.73 (+2.56%)

RCL Royal Caribbean
$89.86 /

+0.08 (+0.09%)

NCLH Norwegian Cruise Line
$30.53 /

-0.08 (-0.26%)

CCL Carnival
$29.30 /

+0.73 (+2.56%)

Hot Stocks
Alibaba fined $2.75B by China for antitrust, vows compliance » 08:39
04/10/21
04/10
08:39
04/10/21
08:39
BABA

Alibaba

$223.35 /

-4.9 (-2.15%)

Alibaba Group Holding…

Alibaba Group Holding announced that it has received the Administrative Penalty Decision issued by the State Administration for Market Regulation of the People's Republic of China. The penalty amounted to $2.75B for the company abusing its dominant position over rivals and merchants on its e-commerce platforms. "Alibaba accepts the penalty with sincerity and will ensure its compliance with determination. To serve its responsibility to society, Alibaba will operate in accordance with the law with utmost diligence, continue to strengthen its compliance systems and build on growth through innovation," the company said in a statement. Reference Link

ShowHide Related Items >><<
BABA Alibaba
$223.35 /

-4.9 (-2.15%)

BABA Alibaba
$223.35 /

-4.9 (-2.15%)

04/09/21 Benchmark
Alibaba price target lowered to $310 from $315 at Benchmark
04/09/21 Morgan Stanley
Alibaba price target lowered to $300 from $320 at Morgan Stanley
04/09/21 Citi
Alibaba price target lowered to $338 from $345 at Citi
04/02/21 CICC
Alibaba initiated with an Outperform at CICC
BABA Alibaba
$223.35 /

-4.9 (-2.15%)

BABA Alibaba
$223.35 /

-4.9 (-2.15%)

BABA Alibaba
$223.35 /

-4.9 (-2.15%)

BABA Alibaba
$223.35 /

-4.9 (-2.15%)

On The Fly
Opening Day: Phone maker UTime soars in public debut » 08:39
04/10/21
04/10
08:39
04/10/21
08:39
SVFD

Save Foods

/

+

, RGCB

Regencell Bioscience

/

+

, RPHM

Reneo Pharmaceuticals

$13.89 /

-1.64 (-10.56%)

, VECT

Vectivbio

$24.01 /

+1.11 (+4.85%)

, UTME

UTime

$48.63 /

+5.53 (+12.83%)

, COIN

Coinbase

/

+

, AGL

Agilon Health

/

+

, SWIM

Latham Group

$10.45 /

+ (+0.00%)

, EDR

Endeavor

$41.49 /

+ (+0.00%)

, UBER

Uber

$57.72 /

-0.11 (-0.19%)

, LYFT

Lyft

$60.96 /

-1.07 (-1.72%)

, PFE

Pfizer

$36.60 /

+0.64 (+1.78%)

, INTM

Intermedia Cloud

/

+

Shares of China-based…

ShowHide Related Items >><<
UTME UTime
$48.63 /

+5.53 (+12.83%)

UBER Uber
$57.72 /

-0.11 (-0.19%)

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LYFT Lyft
$60.96 /

-1.07 (-1.72%)

COIN Coinbase
/

+

SVFD Save Foods
/

+

RGCB Regencell Bioscience
/

+

RPHM Reneo Pharmaceuticals
$13.89 /

-1.64 (-10.56%)

VECT Vectivbio
$24.01 /

+1.11 (+4.85%)

UTME UTime
$48.63 /

+5.53 (+12.83%)

COIN Coinbase
/

+

04/07/21 JMP Securities
Coinbase report shows 'substantial business momentum,' says JMP Securities
03/03/21
Fly Intel: Top five analyst initiations
03/03/21 DA Davidson
Coinbase initiated with a Buy at DA Davidson
AGL Agilon Health
/

+

SWIM Latham Group
$10.45 /

+ (+0.00%)

EDR Endeavor
$41.49 /

+ (+0.00%)

UBER Uber
$57.72 /

-0.11 (-0.19%)

04/05/21 Evercore ISI
Uber assumed with an Outperform at Evercore ISI
04/01/21
Fly Intel: Top five analyst initiations
04/01/21 Jefferies
Uber initiated with a Buy at Jefferies
03/31/21 Wolfe Research
Uber assumed with an Outperform at Wolfe Research
LYFT Lyft
$60.96 /

-1.07 (-1.72%)

04/05/21 Evercore ISI
Lyft assumed with an Outperform at Evercore ISI
03/31/21 Wolfe Research
Lyft assumed with a Peer Perform at Wolfe Research
03/26/21
Fly Intel: Top five analyst initiations
03/26/21 Vertical Research
Lyft initiated with a Buy at Vertical Research
PFE Pfizer
$36.60 /

+0.64 (+1.78%)

04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
INTM Intermedia Cloud
/

+

UBER Uber
$57.72 /

-0.11 (-0.19%)

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LYFT Lyft
$60.96 /

-1.07 (-1.72%)

COIN Coinbase
/

+

  • 15
    Apr
  • 09
    Apr
  • 09
    Apr
  • 07
    Apr
  • 01
    Apr
  • 08
    Jan
UBER Uber
$57.72 /

-0.11 (-0.19%)

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LYFT Lyft
$60.96 /

-1.07 (-1.72%)

COIN Coinbase
/

+

UBER Uber
$57.72 /

-0.11 (-0.19%)

SVFD Save Foods
/

+

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LYFT Lyft
$60.96 /

-1.07 (-1.72%)

COIN Coinbase
/

+

UBER Uber
$57.72 /

-0.11 (-0.19%)

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LYFT Lyft
$60.96 /

-1.07 (-1.72%)

Conference/Events
American Association for Cancer Research to hold a virtual meeting » 04:55
04/10/21
04/10
04:55
04/10/21
04:55
MDGEF

MediGene

$4.80 /

+ (+0.00%)

, GLSI

Greenwich LifeSciences

$53.50 /

+4.21 (+8.54%)

, JNCE

Jounce Therapeutics

$9.76 /

-0.65 (-6.24%)

, ATNM

Actinium Pharmaceuticals

$8.10 /

-0.085 (-1.04%)

, BDTX

Black Diamond Therapeutics

$24.61 /

-0.31 (-1.24%)

, CRSP

Crispr Therapeutics

$115.49 /

-4.67 (-3.89%)

, HARP

Harpoon Therapeutics

$22.70 /

-0.03 (-0.13%)

, ITOS

iTeos Therapeutics

$26.99 /

-3.12 (-10.36%)

, REPL

Replimune Group

$30.04 /

-0.52 (-1.70%)

, RVMD

Revolution Medicines

$42.65 /

-2.46 (-5.45%)

, ZNTL

Zentalis

$37.35 /

-5.19 (-12.20%)

, IMCR

Immunocore

$35.01 /

-0.99 (-2.75%)

, PMVP

PMV Pharmaceuticals

$33.30 /

-0.605 (-1.78%)

, ARVN

Arvinas

$63.55 /

-0.83 (-1.29%)

, IOVA

Iovance Biotherapeutics

$30.17 /

-1.12 (-3.58%)

, ADXS

Advaxis

/

+

, AGEN

Agenus

$2.78 /

-0.01 (-0.36%)

, BPTH

Bio-Path

$6.79 /

-0.13 (-1.88%)

, INCY

Incyte

$79.97 /

-0.91 (-1.13%)

, IMAB

I-MAB

$51.50 /

-1.34 (-2.54%)

, MRSN

Mersana Therapeutics

$15.79 /

-0.27 (-1.68%)

, RUBY

Rubius Therapeutics

$23.92 /

-0.14 (-0.58%)

, PPBT

Purple Biotech

$4.31 /

+0.035 (+0.82%)

, SONN

Sonnet BioTherapeutics

$2.24 /

-0.05 (-2.18%)

, STTK

Shattuck Labs

$28.31 /

+1.365 (+5.07%)

, SURF

Surface Oncology

$7.93 /

-0.22 (-2.70%)

, BGNE

BeiGene

$308.27 /

-5.8 (-1.85%)

, CMPI

Checkmate Pharmaceuticals

$10.52 /

+0.14 (+1.35%)

, BNGO

Bionano Genomics

$7.29 /

-0.215 (-2.87%)

AACR Virtual Annual…

AACR Virtual Annual Meeting 2021 will be held on April 9-15. Webcast Link

ShowHide Related Items >><<
ZNTL Zentalis
$37.35 /

-5.19 (-12.20%)

SURF Surface Oncology
$7.93 /

-0.22 (-2.70%)

STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

SONN Sonnet BioTherapeutics
$2.24 /

-0.05 (-2.18%)

RVMD Revolution Medicines
$42.65 /

-2.46 (-5.45%)

RUBY Rubius Therapeutics
$23.92 /

-0.14 (-0.58%)

REPL Replimune Group
$30.04 /

-0.52 (-1.70%)

PPBT Purple Biotech
$4.31 /

+0.035 (+0.82%)

PMVP PMV Pharmaceuticals
$33.30 /

-0.605 (-1.78%)

MRSN Mersana Therapeutics
$15.79 /

-0.27 (-1.68%)

JNCE Jounce Therapeutics
$9.76 /

-0.65 (-6.24%)

ITOS iTeos Therapeutics
$26.99 /

-3.12 (-10.36%)

IOVA Iovance Biotherapeutics
$30.17 /

-1.12 (-3.58%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

IMCR Immunocore
$35.01 /

-0.99 (-2.75%)

IMAB I-MAB
$51.50 /

-1.34 (-2.54%)

HARP Harpoon Therapeutics
$22.70 /

-0.03 (-0.13%)

GLSI Greenwich LifeSciences
$53.50 /

+4.21 (+8.54%)

CRSP Crispr Therapeutics
$115.49 /

-4.67 (-3.89%)

CMPI Checkmate Pharmaceuticals
$10.52 /

+0.14 (+1.35%)

BPTH Bio-Path
$6.79 /

-0.13 (-1.88%)

BNGO Bionano Genomics
$7.29 /

-0.215 (-2.87%)

BGNE BeiGene
$308.27 /

-5.8 (-1.85%)

BDTX Black Diamond Therapeutics
$24.61 /

-0.31 (-1.24%)

ATNM Actinium Pharmaceuticals
$8.10 /

-0.085 (-1.04%)

ARVN Arvinas
$63.55 /

-0.83 (-1.29%)

AGEN Agenus
$2.78 /

-0.01 (-0.36%)

ADXS Advaxis
/

+

MDGEF MediGene
$4.80 /

+ (+0.00%)

GLSI Greenwich LifeSciences
$53.50 /

+4.21 (+8.54%)

JNCE Jounce Therapeutics
$9.76 /

-0.65 (-6.24%)

03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
12/04/20 H.C. Wainwright
Jounce Therapeutics assumed with a Buy at H.C. Wainwright
11/10/20 Roth Capital
Jounce Therapeutics price target lowered to $15 from $28 at Roth Capital
ATNM Actinium Pharmaceuticals
$8.10 /

-0.085 (-1.04%)

04/06/21 William Blair
Actinium's Q4 net loss roughly in line with projected loss, says William Blair
12/29/20 H.C. Wainwright
H.C. Wainwright keeps Buy on Actinium amid 'headline disappointment'
12/29/20 JonesTrading
Actinium selloff today 'clear buying opportunity,' says JonesTrading
11/05/20
Fly Intel: Top five analyst initiations
BDTX Black Diamond Therapeutics
$24.61 /

-0.31 (-1.24%)

03/29/21 Wedbush
Black Diamond Therapeutics added to Best Ideas List at Wedbush
01/07/21 Wedbush
Wedbush bullish on Black Diamond Therapeutics, initiates with an Outperform
01/06/21 Wedbush
Black Diamond Therapeutics initiated with an Outperform at Wedbush
11/24/20 Berenberg
Black Diamond Therapeutics initiated with a Buy at Berenberg
CRSP Crispr Therapeutics
$115.49 /

-4.67 (-3.89%)

03/17/21 Guggenheim
Editas Medicine assumed with a Neutral at Guggenheim
03/04/21 JMP Securities
Crispr Therapeutics initiated with an Outperform at JMP Securities
03/01/21 Barclays
Crispr Therapeutics price target raised to $140 from $113 at Barclays
02/17/21 Goldman Sachs
Crispr Therapeutics price target lowered to $189 from $193 at Goldman Sachs
HARP Harpoon Therapeutics
$22.70 /

-0.03 (-0.13%)

03/11/21 Roth Capital
Harpoon's 2020/2021 should be 'festival of data,' says Roth Capital
01/04/21 Roth Capital
Harpoon having fourth candidate in clinic 'impressive,' says Roth Capital
12/23/20 H.C. Wainwright
Harpoon Therapeutics assumed with a Buy at H.C. Wainwright
12/16/20 Wedbush
Replimune Group, Harpoon Therapeutics removed from Best Ideas List at Wedbush
ITOS iTeos Therapeutics
$26.99 /

-3.12 (-10.36%)

04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
04/05/21 Piper Sandler
Piper Sandler continues to recommend iTeos Therapeutics into data
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
REPL Replimune Group
$30.04 /

-0.52 (-1.70%)

02/05/21 H.C. Wainwright
Replimune Group price target raised to $60 from $58 at H.C. Wainwright
11/17/20 BTIG
Replimune Group initiated with a Buy at BTIG
11/10/20 H.C. Wainwright
Replimune Group price target raised to $58 from $54 at H.C. Wainwright
RVMD Revolution Medicines
$42.65 /

-2.46 (-5.45%)

03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
ZNTL Zentalis
$37.35 /

-5.19 (-12.20%)

03/26/21 H.C. Wainwright
Zentalis price target raised to $65 from $43 at H.C. Wainwright
01/19/21 Wedbush
Zentalis initiated with an Outperform at Wedbush
09/28/20 Cantor Fitzgerald
Cantor starts 'underappreciated' Zentalis with Overweight, $44 target
09/28/20 Cantor Fitzgerald
Zentalis initiated with an Overweight at Cantor Fitzgerald
IMCR Immunocore
$35.01 /

-0.99 (-2.75%)

03/02/21 Jefferies
Immunocore initiated with a Buy at Jefferies
03/02/21 JPMorgan
Immunocore initiated with an Overweight at JPMorgan
03/02/21 Goldman Sachs
Immunocore initiated with a Neutral at Goldman Sachs
PMVP PMV Pharmaceuticals
$33.30 /

-0.605 (-1.78%)

10/20/20 Evercore ISI
PMV Pharmaceuticals initiated with an Outperform at Evercore ISI
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 Cowen
PMV Pharmaceuticals initiated with an Outperform at Cowen
ARVN Arvinas
$63.55 /

-0.83 (-1.29%)

03/31/21 BMO Capital
Arvinas initiated with an Outperform at BMO Capital
03/30/21 Cantor Fitzgerald
Arvinas price target raised to $140 from $121 at Cantor Fitzgerald
03/01/21 Roth Capital
Arvinas reaffirmed 'major catalysts' for 2021, says Roth Capital
01/19/21 Oppenheimer
Arvinas price target raised to $100 from $80 at Oppenheimer
IOVA Iovance Biotherapeutics
$30.17 /

-1.12 (-3.58%)

03/08/21 H.C. Wainwright
Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright
01/29/21 Baird
Iovance Biotherapeutics assumed at Outperform at Baird
01/14/21 Oppenheimer
Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer
12/17/20 Barclays
Iovance Biotherapeutics price target raised to $55 from $43 at Barclays
ADXS Advaxis
/

+

AGEN Agenus
$2.78 /

-0.01 (-0.36%)

09/22/20 B. Riley
B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases
09/18/20 Jefferies
Agenus price target raised to $8 from $5 at Jefferies
BPTH Bio-Path
$6.79 /

-0.13 (-1.88%)

04/06/21 H.C. Wainwright
Bio-Path price target raised to $12 from $10 at H.C. Wainwright
04/05/21 Roth Capital
Bio-Path triple regimen data 'highly favorable,' says Roth Capital
03/11/21 Roth Capital
Bio-Path Holdings initiated with a Buy at Roth Capital
11/16/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $10 from $12 at H.C. Wainwright
INCY Incyte
$79.97 /

-0.91 (-1.13%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
IMAB I-MAB
$51.50 /

-1.34 (-2.54%)

03/15/21 Needham
I-MAB initiated with a Buy at Needham
03/03/21 H.C. Wainwright
I-MAB price target raised to $75 from $55 at H.C. Wainwright
02/25/21
Fly Intel: Top five analyst initiations
02/25/21 Piper Sandler
I-MAB initiated with an Overweight at Piper Sandler
MRSN Mersana Therapeutics
$15.79 /

-0.27 (-1.68%)

03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
12/02/20 Stifel
Mersana Therapeutics initiated with a Buy at Stifel
09/29/20 JPMorgan
Mersana Therapeutics resumed with a Neutral at JPMorgan
RUBY Rubius Therapeutics
$23.92 /

-0.14 (-0.58%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
PPBT Purple Biotech
$4.31 /

+0.035 (+0.82%)

12/31/20 H.C. Wainwright
H.C. Wainwright reiterates Buy, $25 price target on Purple Biotech
SONN Sonnet BioTherapeutics
$2.24 /

-0.05 (-2.18%)

09/04/20 Chardan
Sonnet BioTherapeutics price target raised to $8 from $7 at Chardan
06/05/20 Chardan
Sonnet BioTherapeutics initiated with a Buy at Chardan
STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
01/11/21 Evercore ISI
Shattuck Labs initiated with an Outperform at Evercore ISI
11/03/20 Needham
Shattuck Labs initiated with a Buy at Needham
11/03/20 Citi
Shattuck Labs initiated with a Buy at Citi
SURF Surface Oncology
$7.93 /

-0.22 (-2.70%)

03/10/21 Wedbush
Surface Oncology risk/reward 'highly favorable' into data, says Wedbush
12/18/20 H.C. Wainwright
Surface Oncology price target raised to $15 from $11 at H.C. Wainwright
09/04/20
Fly Intel: Top five analyst initiations
09/04/20 H.C. Wainwright
Surface Oncology initiated with a Buy at H.C. Wainwright
BGNE BeiGene
$308.27 /

-5.8 (-1.85%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
CMPI Checkmate Pharmaceuticals
$10.52 /

+0.14 (+1.35%)

03/19/21 Jefferies
Checkmate Pharmaceuticals price target lowered to $19 from $23 at Jefferies
09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
09/01/20 BofA
BofA starts Checkmate Pharmaceuticals at Neutral ahead of more 'de-risking'
09/01/20 BofA
Checkmate Pharmaceuticals initiated with a Neutral at BofA
BNGO Bionano Genomics
$7.29 /

-0.215 (-2.87%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
ZNTL Zentalis
$37.35 /

-5.19 (-12.20%)

SURF Surface Oncology
$7.93 /

-0.22 (-2.70%)

STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

RVMD Revolution Medicines
$42.65 /

-2.46 (-5.45%)

RUBY Rubius Therapeutics
$23.92 /

-0.14 (-0.58%)

REPL Replimune Group
$30.04 /

-0.52 (-1.70%)

PMVP PMV Pharmaceuticals
$33.30 /

-0.605 (-1.78%)

MRSN Mersana Therapeutics
$15.79 /

-0.27 (-1.68%)

JNCE Jounce Therapeutics
$9.76 /

-0.65 (-6.24%)

ITOS iTeos Therapeutics
$26.99 /

-3.12 (-10.36%)

IOVA Iovance Biotherapeutics
$30.17 /

-1.12 (-3.58%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

IMCR Immunocore
$35.01 /

-0.99 (-2.75%)

HARP Harpoon Therapeutics
$22.70 /

-0.03 (-0.13%)

CRSP Crispr Therapeutics
$115.49 /

-4.67 (-3.89%)

CMPI Checkmate Pharmaceuticals
$10.52 /

+0.14 (+1.35%)

BPTH Bio-Path
$6.79 /

-0.13 (-1.88%)

BNGO Bionano Genomics
$7.29 /

-0.215 (-2.87%)

BGNE BeiGene
$308.27 /

-5.8 (-1.85%)

BDTX Black Diamond Therapeutics
$24.61 /

-0.31 (-1.24%)

ARVN Arvinas
$63.55 /

-0.83 (-1.29%)

AGEN Agenus
$2.78 /

-0.01 (-0.36%)

ADXS Advaxis
/

+

  • 17
    Mar
  • 10
    Mar
  • 16
    Feb
  • 09
    Feb
  • 04
    Feb
  • 05
    Feb
  • 20
    Jan
  • 13
    Jan
  • 08
    Jan
  • 07
    Jan
  • 18
    Dec
  • 16
    Dec
  • 02
    Dec
  • 24
    Nov
  • 22
    Oct
  • 09
    Oct
  • 25
    Sep
  • 25
    Sep
  • 07
    Aug
  • 30
    Jul
  • 24
    Jul
  • 09
    Jul
  • 01
    Jul
  • 17
    Jun
  • 09
    Jun
  • 29
    May
  • 29
    May
  • 22
    Apr
INCY Incyte
$79.97 /

-0.91 (-1.13%)

GLSI Greenwich LifeSciences
$53.50 /

+4.21 (+8.54%)

SURF Surface Oncology
$7.93 /

-0.22 (-2.70%)

STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

RVMD Revolution Medicines
$42.65 /

-2.46 (-5.45%)

RUBY Rubius Therapeutics
$23.92 /

-0.14 (-0.58%)

REPL Replimune Group
$30.04 /

-0.52 (-1.70%)

MRSN Mersana Therapeutics
$15.79 /

-0.27 (-1.68%)

JNCE Jounce Therapeutics
$9.76 /

-0.65 (-6.24%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

IMCR Immunocore
$35.01 /

-0.99 (-2.75%)

HARP Harpoon Therapeutics
$22.70 /

-0.03 (-0.13%)

GLSI Greenwich LifeSciences
$53.50 /

+4.21 (+8.54%)

CRSP Crispr Therapeutics
$115.49 /

-4.67 (-3.89%)

BNGO Bionano Genomics
$7.29 /

-0.215 (-2.87%)

ATNM Actinium Pharmaceuticals
$8.10 /

-0.085 (-1.04%)

ARVN Arvinas
$63.55 /

-0.83 (-1.29%)

ZNTL Zentalis
$37.35 /

-5.19 (-12.20%)

RVMD Revolution Medicines
$42.65 /

-2.46 (-5.45%)

REPL Replimune Group
$30.04 /

-0.52 (-1.70%)

PPBT Purple Biotech
$4.31 /

+0.035 (+0.82%)

PMVP PMV Pharmaceuticals
$33.30 /

-0.605 (-1.78%)

INCY Incyte
$79.97 /

-0.91 (-1.13%)

CRSP Crispr Therapeutics
$115.49 /

-4.67 (-3.89%)

BNGO Bionano Genomics
$7.29 /

-0.215 (-2.87%)

BDTX Black Diamond Therapeutics
$24.61 /

-0.31 (-1.24%)

Hot Stocks
Condor Hospitality Trust says annual report contains 'going concern' paragraph » 18:10
04/09/21
04/09
18:10
04/09/21
18:10
CDOR

Condor Hospitality Trust

$3.58 /

-0.09 (-2.45%)

Hospitality Trust,…

Hospitality Trust, pursuant to the disclosure requirements of the NYSE American Company Guidelines Sections 401(h) and 610(b), the company advises that its audited financial statements for the fiscal year ended December 31, 2020, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 as filed with the SEC, contains an audit opinion from its independent registered public accounting firm that due to circumstances related to a loan includes an explanatory paragraph related to the company's ability to continue as a going concern. Matters relating to this item are set forth in the Form 10-K, where the company expresses its views with respect to third party actions related to a specific loan, the underlying reason for the going concern paragraph. This advisement does not represent any change or amendment to the company's financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

ShowHide Related Items >><<
CDOR Condor Hospitality Trust
$3.58 /

-0.09 (-2.45%)

CDOR Condor Hospitality Trust
$3.58 /

-0.09 (-2.45%)

10/21/20 B. Riley
Condor Hospitality price target lowered to $4 from $5 at B. Riley Securities
Hot Stocks
J.M. Smucker announces limited recall of two lots of Meow Mix dry cat food » 17:40
04/09/21
04/09
17:40
04/09/21
17:40
SJM

J.M. Smucker

$128.22 /

+0.13 (+0.10%)

J. M. Smucker announced a…

J. M. Smucker announced a limited, voluntary recall of two lots of Meow Mix Original Choice Dry Cat Food due to potential salmonella contamination. The company said it has received no reports of pet illness or adverse reaction and has issued this recall out of an abundance of caution. The impacted products were sold at select Walmart stores in Illinois, Missouri, Nebraska, New Mexico, Oklahoma, Utah, Wisconsin and Wyoming. No other Meow Mix products are impacted by this recall. The company also said if pet parents have products matching the following description in their possession, they should stop feeding it to their cats and dispose of it immediately.

ShowHide Related Items >><<
SJM J.M. Smucker
$128.22 /

+0.13 (+0.10%)

SJM J.M. Smucker
$128.22 /

+0.13 (+0.10%)

01/20/21 Citi
J.M. Smucker initiated with a Neutral at Citi
01/19/21 JPMorgan
J.M. Smucker price target lowered to $115 from $122 at JPMorgan
09/16/20 Morgan Stanley
J.M. Smucker price target lowered to $106 from $114 at Morgan Stanley
08/26/20
Fly Intel: Top five analyst upgrades
SJM J.M. Smucker
$128.22 /

+0.13 (+0.10%)

SJM J.M. Smucker
$128.22 /

+0.13 (+0.10%)

SJM J.M. Smucker
$128.22 /

+0.13 (+0.10%)

Hot Stocks
Electronic Arts CFO sells 5,975 shares of common stock » 17:40
04/09/21
04/09
17:40
04/09/21
17:40
EA

Electronic Arts

$140.36 /

-1.12 (-0.79%)

In a regulatory filing,…

In a regulatory filing, Electronic Arts disclosed that its CFO Gerald Volas sold 5,975 shares of common stock on April 7th in a total transaction size of $848K, reducing his stake by about 17%.

ShowHide Related Items >><<
EA Electronic Arts
$140.36 /

-1.12 (-0.79%)

EA Electronic Arts
$140.36 /

-1.12 (-0.79%)

02/11/21 Benchmark
Glu Mobile downgraded to Hold from Buy at Benchmark
02/10/21 Cowen
Glu Mobile downgraded to Market Perform from Outperform at Cowen
02/09/21 Stifel
Glu Mobile downgraded to Hold from Buy at Stifel
02/09/21 KeyBanc
EA, Glu Mobile deal 'a smart strategic move,' says KeyBanc
EA Electronic Arts
$140.36 /

-1.12 (-0.79%)

EA Electronic Arts
$140.36 /

-1.12 (-0.79%)

EA Electronic Arts
$140.36 /

-1.12 (-0.79%)

EA Electronic Arts
$140.36 /

-1.12 (-0.79%)

Syndicate
Sorrento Therapeutics files to sell 851,305 shares of common stock for holders  17:08
04/09/21
04/09
17:08
04/09/21
17:08
SRNE

Sorrento Therapeutics

$7.50 /

-0.235 (-3.04%)

 
ShowHide Related Items >><<
SRNE Sorrento Therapeutics
$7.50 /

-0.235 (-3.04%)

SRNE Sorrento Therapeutics
$7.50 /

-0.235 (-3.04%)

03/26/21 B. Riley
Sorrento data make case for expedited EUA filing path, says B. Riley Securities
01/29/21 B. Riley
Sorrento Therapeutics initiated with a Buy at B. Riley Securities
01/21/21 Alliance Global Partners
Sorrento Therapeutics initiated with a Buy at Alliance Global Partners
07/31/20 H.C. Wainwright
Sorrento Therapeutics price target raised to $30 from $24 at H.C. Wainwright
SRNE Sorrento Therapeutics
$7.50 /

-0.235 (-3.04%)

SRNE Sorrento Therapeutics
$7.50 /

-0.235 (-3.04%)

Hot Stocks
Tractor Supply, Orscheln Farm and Home receive FTC request for additional info » 17:07
04/09/21
04/09
17:07
04/09/21
17:07
TSCO

Tractor Supply

$177.59 /

+0.98 (+0.55%)

Tractor Supply announced…

Tractor Supply announced that it and Orscheln Farm and Home have each received a request for additional information and documentary materials from the Federal Trade Commission, or FTC, in connection with Tractor Supply's pending acquisition of Orscheln Farm and Home. The second request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The effect of the second request is to extend the applicable waiting period relating to the pending acquisition until 30 days after Tractor Supply and Orscheln Farm and Home have complied with the second request, unless the waiting period is terminated earlier by the FTC or voluntarily extended by Tractor Supply and Orscheln Farm and Home. Tractor Supply and Orscheln Farm and Home said they continue to cooperate fully with the FTC in its review of the pending acquisition.

ShowHide Related Items >><<
TSCO Tractor Supply
$177.59 /

+0.98 (+0.55%)

TSCO Tractor Supply
$177.59 /

+0.98 (+0.55%)

04/07/21 Guggenheim
Tractor Supply price target raised to $200 from $180 at Guggenheim
03/29/21 Wells Fargo
Tractor Supply price target raised to $200 from $180 at Wells Fargo
03/09/21 Citi
Citi starts Best Buy with Sell, sees 'too many red flags'
03/08/21 Citi
Tractor Supply initiated with a Neutral at Citi
TSCO Tractor Supply
$177.59 /

+0.98 (+0.55%)

TSCO Tractor Supply
$177.59 /

+0.98 (+0.55%)

TSCO Tractor Supply
$177.59 /

+0.98 (+0.55%)

Periodicals
GM to cut overtime production at two U.S. truck plants this weekend, CNBC says » 17:05
04/09/21
04/09
17:05
04/09/21
17:05
GM

General Motors

$60.15 /

+0.08 (+0.13%)

General Motors is…

General Motors is slashing overtime output this weekend at two U.S. assembly facilities that make its full-size pickups due to the ongoing chip shortage affecting the global car industry, CNBC's Michael Wayland reports. The factories in Flint, Michigan and Fort Wayne, Indiana manufacture a mix of the car maker's full-size pickups, the author notes. Reference Link

ShowHide Related Items >><<
GM General Motors
$60.15 /

+0.08 (+0.13%)

GM General Motors
$60.15 /

+0.08 (+0.13%)

04/05/21
Fly Intel: Top five analyst initiations
04/05/21 Wells Fargo
General Motors initiated with an Overweight at Wells Fargo
03/29/21 Jefferies
General Motors price target raised to $62 from $50 at Jefferies
03/24/21 Morgan Stanley
American Axle downgraded to Underweight on ICE phase out risk at Morgan Stanley
GM General Motors
$60.15 /

+0.08 (+0.13%)

GM General Motors
$60.15 /

+0.08 (+0.13%)

GM General Motors
$60.15 /

+0.08 (+0.13%)

GM General Motors
$60.15 /

+0.08 (+0.13%)

Hot Stocks
Cameco restarting Cigar Lake mine in April » 17:01
04/09/21
04/09
17:01
04/09/21
17:01
CCJ

Cameco

$17.22 /

-0.425 (-2.41%)

Cameco announced that it…

Cameco announced that it plans to restart production in April at its Cigar Lake uranium mine located in northern Saskatchewan. Production at Cigar Lake was temporarily suspended in December 2020 due to increasing risks posed by the Coronavirus (COVID-19) pandemic. At that time, the availability of workers in critical areas was shrinking due to the pandemic, with more individuals screening out or residing in communities with pandemic-related travel restrictions. "The safety of our workers, their families and communities is always our top priority," said Cameco president and CEO Tim Gitzel. "In recent months we have implemented several enhanced safety protocols for Cigar Lake, including increased distancing between passengers on flights, mandatory medical-grade masks for all workers and increased sanitization and physical barriers in our eating areas. We also worked with the Saskatchewan Health Authority and have established a licensed COVID-19 testing facility at the mine site. These further safety measures, along with the provincial vaccine rollout program and increased confidence around our ability to manage our critical workforce, have given us greater certainty that Cigar Lake will be able to operate safely and sustainably." As the restart process begins, Cameco will closely monitor the COVID-19 case counts and the ongoing success of the vaccine rollout, and will continue to have regular dialogue with public health authorities and northern Saskatchewan leaders.

ShowHide Related Items >><<
CCJ Cameco
$17.22 /

-0.425 (-2.41%)

CCJ Cameco
$17.22 /

-0.425 (-2.41%)

02/12/21 BMO Capital
Cameco price target raised to C$23 from C$18.50 at BMO Capital
02/11/21 Scotiabank
Cameco price target raised to C$23 from C$22 at Scotiabank
02/11/21 TD Securities
Cameco price target raised to C$20 from C$18 at TD Securities
02/11/21 BofA
Cameco downgraded to Neutral from Buy at BofA
CCJ Cameco
$17.22 /

-0.425 (-2.41%)

CCJ Cameco
$17.22 /

-0.425 (-2.41%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.